Keyphrases
Non-small Cell Lung Cancer Patients
100%
Tyrosine Kinase Inhibitor Therapy
100%
Brain Metastases
100%
Stereotactic Radiosurgery
100%
EGFR mutation
33%
Tumor Control
33%
Overall Survival Rate
25%
Overall Survival
16%
Clinical Outcomes
8%
Between-group
8%
Seizure
8%
Tumor Volume
8%
Old Age
8%
Tyrosine Kinase Inhibitor
8%
Potential Gains
8%
Group-based
8%
Cox Regression Analysis
8%
Disease Progression
8%
Survival Rate
8%
Radiation Therapy
8%
Kaplan-Meier Analysis
8%
Disease Control
8%
Extracranial
8%
Therapy Groups
8%
Multivariable Cox Regression
8%
Neurological Deficit
8%
Tumor Control Rate
8%
Intracranial Metastases
8%
Salvage Therapy
8%
Karnofsky Performance Status
8%
Effects on Survival
8%
Performance Status Score
8%
Intracranial Tumor
8%
Outcome Benefits
8%
Intracranial Disease
8%
Medicine and Dentistry
Tyrosine-Kinase Inhibitor
100%
Treatment of Non-Small Cell Lung Cancer
100%
Brain Metastasis
100%
Stereotactic Radiosurgery
100%
Neoplasm
38%
Overall Survival
38%
Non Small Cell Lung Cancer
30%
Survival Rate
30%
Epidermal Growth Factor Receptor
30%
Cohort Analysis
7%
Epileptic Seizure
7%
Metastatic Carcinoma
7%
Proportional Hazards Model
7%
Disease Exacerbation
7%
Prospective Study
7%
Kaplan Meier Method
7%
Group Therapy
7%
Salvage Therapy
7%
Intracranial Tumor
7%
Karnofsky Performance Status
7%
Diseases
7%
Radiation Therapy
7%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Protein Tyrosine Kinase Inhibitor
100%
Brain Metastasis
100%
Neoplasm
38%
Overall Survival
38%
Epidermal Growth Factor Receptor
30%
Survival Rate
30%
Prospective Study
7%
Disease Exacerbation
7%
Cohort Study
7%
Intracranial Tumor
7%
Diseases
7%
Neuroscience
Tyrosine Kinase Inhibitor
100%
Epidermal Growth Factor Receptor
30%
Group Therapy
7%
Intracranial Tumor
7%
Radiation Therapy
7%